Literature DB >> 25384936

Commentary on Nolan et al. (2014): Opiate substitution treatment and hepatitis C virus prevention: building an evidence base?

Peter Vickerman1, Kimberly Page, Lisa Maher, Matthew Hickman.   

Abstract

Entities:  

Keywords:  Buprenorphine; hepatitis C; injecting drug use; methadone maintenance therapy; opiate substitution treatment; prevention

Mesh：

Substances：

Year:  2014        PMID： 25384936      PMCID： PMC4520398          DOI： 10.1111/add.12750

Source DB:  PubMed          Journal:  Addiction        ISSN： 0965-2140            Impact factor:   6.526


× No keyword cloud information.
  18 in total

Review 1.  Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies.

Authors:  Louisa Degenhardt; Chiara Bucello; Bradley Mathers; Christina Briegleb; Hammad Ali; Matt Hickman; Jennifer McLaren
Journal:  Addiction       Date:  2010-11-04       Impact factor: 6.526

2.  Addiction treatment-related employment barriers: the impact of methadone maintenance.

Authors:  Lindsey Richardson; Evan Wood; Julio Montaner; Thomas Kerr
Journal:  J Subst Abuse Treat       Date:  2012-02-01

3.  Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users.

Authors:  Judith A Hahn; Dennis Wylie; Jesse Dill; Maria S Sanchez; James O Lloyd-Smith; Kimberly Page-Shafer; Wayne M Getz
Journal:  Epidemics       Date:  2009-03       Impact factor: 4.396

4.  The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.

Authors:  Katy M E Turner; Sharon Hutchinson; Peter Vickerman; Vivian Hope; Noel Craine; Norah Palmateer; Margaret May; Avril Taylor; Daniela De Angelis; Sheila Cameron; John Parry; Margaret Lyons; David Goldberg; Elizabeth Allen; Matthew Hickman
Journal:  Addiction       Date:  2011-08-24       Impact factor: 6.526

5.  The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users.

Authors:  Seonaid Nolan; Viviane Dias Lima; Nadia Fairbairn; Thomas Kerr; Julio Montaner; Jason Grebely; Evan Wood
Journal:  Addiction       Date:  2014-08-14       Impact factor: 6.526

Review 6.  A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs.

Authors:  Holly Hagan; Enrique R Pouget; Don C Des Jarlais
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

7.  Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings.

Authors:  Peter Vickerman; Natasha Martin; Katy Turner; Matthew Hickman
Journal:  Addiction       Date:  2012-07-12       Impact factor: 6.526

Review 8.  Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness.

Authors:  Georgina J MacArthur; Eva van Velzen; Norah Palmateer; Jo Kimber; Anastasia Pharris; Vivian Hope; Avril Taylor; Kirsty Roy; Esther Aspinall; David Goldberg; Tim Rhodes; Dagmar Hedrich; Mika Salminen; Matthew Hickman; Sharon J Hutchinson
Journal:  Int J Drug Policy       Date:  2013-08-21

9.  Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.

Authors:  Natasha K Martin; Matthew Hickman; Sharon J Hutchinson; David J Goldberg; Peter Vickerman
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

Review 10.  Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis.

Authors:  Georgie J MacArthur; Silvia Minozzi; Natasha Martin; Peter Vickerman; Sherry Deren; Julie Bruneau; Louisa Degenhardt; Matthew Hickman
Journal:  BMJ       Date:  2012-10-03
View more
  7 in total

Review 1.  Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C.

Authors:  Asher J Schranz; Jessica Barrett; Christopher B Hurt; Carlos Malvestutto; William C Miller
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

2.  Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?

Authors:  Ilias Gountas; Vana Sypsa; Olga Anagnostou; Natasha Martin; Peter Vickerman; Evangelos Kafetzopoulos; Angelos Hatzakis
Journal:  Addiction       Date:  2017-02-17       Impact factor: 6.526

3.  Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic.

Authors:  Hannah Fraser; Jon Zibbell; Thomas Hoerger; Susan Hariri; Claudia Vellozzi; Natasha K Martin; Alex H Kral; Matthew Hickman; John W Ward; Peter Vickerman
Journal:  Addiction       Date:  2017-09-20       Impact factor: 6.526

Review 4.  The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges?

Authors:  Stine Bordier Høj; Nanor Minoyan; Andreea Adelina Artenie; Jason Grebely; Julie Bruneau
Journal:  Can Liver J       Date:  2018-07-17

5.  Importance and Contribution of Community, Social, and Healthcare Risk Factors for Hepatitis C Infection in Pakistan.

Authors:  Adam Trickey; Margaret T May; Charlotte Davies; Huma Qureshi; Saeed Hamid; Hassan Mahmood; Quaid Saeed; Matthew Hickman; Nancy Glass; Francisco Averhoff; Peter Vickerman
Journal:  Am J Trop Med Hyg       Date:  2017-10-12       Impact factor: 2.345

6.  Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV.

Authors:  Jim Young; Carmine Rossi; John Gill; Sharon Walmsley; Curtis Cooper; Joseph Cox; Valerie Martel-Laferriere; Brian Conway; Neora Pick; Marie-Louise Vachon; Marina B Klein
Journal:  Clin Infect Dis       Date:  2017-05-01       Impact factor: 9.079

7.  HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era.

Authors:  Ilias Gountas; Vana Sypsa; Sarah Blach; Homie Razavi; Angelos Hatzakis
Journal:  PLoS One       Date:  2018-08-16       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.